Form 4: BioXcel Therapeutics Director David J. Mack Reports Stock Transactions
SEC Form 4 Filing
Director David J. Mack reports the vesting of restricted stock units and subsequent disposal of shares.
Summary
- On February 28, 2025, David J. Mack, a director of BioXcel Therapeutics, Inc., reported transactions involving the company's common stock.
- Mack acquired 1,693 shares through the vesting of restricted stock units (RSUs).
- Simultaneously, Mack disposed of 6,772 shares.
- Following these transactions, Mack directly owns 13,545 derivative securities (RSUs).
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of company directors and officers.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the director's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| November 21, 2024 | Reporting Person was granted 20,317 RSUs |
| November 30, 2024 | RSUs vesting in twelve equal installments on the last day of each month beginning on this date |
| February 28, 2025 | Date of transaction: acquisition of 1,693 shares via RSU vesting and disposal of 6,772 shares |
| March 04, 2025 | Date of filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.